| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is making significant strides in product development, particularly with advancements in treatments for conditions like atopic dermatitis, psoriatic arthritis, and obesity. The company's commitment to integrating artificial intelligence is revolutionizing drug discovery, enhancing both efficiency and effectiveness. Recent acquisitions and expansions into new therapeutic areas such as sleep medicine demonstrate a proactive approach to diversifying its product pipeline. Furthermore, successful clinical trials and FDA approvals indicate a strong potential for growth and improved patient outcomes. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 0.9 is bullish. The market sentiment at 0.8 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. LLY is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 1.1, and the negative at -0.3 on 2026-04-01. The forces of Sentiment towards Fundamentals (4.6), Stock Price Trend (0.9), Option Sentiment (0.8), Sector Price Trend (0.4), and Price Level Sentiment (0) will drive up the price. The forces of Valuation Sentiment (-0.9), and Market Risk Appetite (-1) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | 1%(0.7%) | 954.28 | 4.45% | 56 | 3.71% | 0.4% | 0.9 | 0 | 1% | 0.8 | Long | 55% | 4.6 | 6.6 |
| 2026-03-31 | 1%(0.6%) | 920.11 | 4.82% | 35 | 3.78% | -0.11% | -0.2 | -0.9 | 1.3% | 0.4 | Short | 55% | 4.4 | 6.6 |
| 2026-03-30 | 1%(0.4%) | 886.63 | 5.17% | 15 | 1.02% | -1.11% | -2.3 | -0.9 | 1.3% | -0.1 | Short | 65% | 4.1 | 6.8 |
| 2026-03-29 | 2%(0.3%) | -2.7 | -0.9 | -0.6 | 3.4 | 7 | ||||||||
| 2026-03-28 | 0%(0%) | -2.7 | -0.9 | -0.7 | 2.8 | -1 | ||||||||
| 2026-03-27 | 0%(0%) | 877.65 | 5.2% | 7 | -2.11% | -1.16% | -2.7 | -0.9 | 1.4% | -0.3 | Short | 55% | 2.6 | -1 |
| 2026-03-26 | 0%(0%) | 896.61 | 5.17% | 13 | -2.16% | -0.86% | -2 | -0.4 | 0.7% | -0 | Short | 65% | 2.5 | -1 |
| 2026-03-25 | 0%(0%) | 916.42 | 4.92% | 19 | 1.54% | -0.88% | -1.5 | 0.2 | 0.7% | 0.4 | Short | 65% | 3.8 | -1 |
| 2026-03-24 | 0%(0%) | 902.53 | 4.97% | 8 | -0.88% | -1.04% | -2.3 | -0.2 | 0.7% | 0.2 | Short | 55% | 3.6 | -1 |
| 2026-03-23 | 0%(0.1%) | 910.54 | 4.78% | 8 | 0.44% | -1.02% | -3.5 | -0.2 | 0.5% | -0.7 | Short | 55% | 0.7 | 4.5 |
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-04-01 22:47:46 The availability of Foundayo through an online pharmacy indicates a trend towards digital health solutions and improving patient access to medications. |
| 2026-04-01 22:47:46 Eli Lilly's new product may affect the competitive positioning of other companies in the weight-loss medication market, particularly Novo Nordisk. |
| 2026-04-01 22:47:46 The introduction of Eli Lilly's weight-loss pill, Foundayo, signifies a significant development in the pharmaceutical market for obesity treatment. |
| 2026-04-01 17:48:07 The approval of new weight-loss drugs by the FDA signifies a positive regulatory impact on the market. |
| 2026-04-01 17:48:07 The entry of new products from competitor companies highlights the competitive nature of the weight-loss drug market. |
| 2026-04-01 17:48:07 The emergence and approval of new weight-loss drugs indicate a significant growth trend in the obesity treatment market. |
| 2026-04-01 17:02:05 Eli Lilly's opposition to proposed drug pricing regulations reflects the ongoing regulatory challenges faced by pharmaceutical companies. |
| 2026-04-01 17:02:05 Eli Lilly's acquisition of Centessa Pharmaceuticals aims to diversify its portfolio beyond obesity, pointing to strategic investment plans. |
| 2026-04-01 17:02:05 Several articles mention the rise in Eli Lilly's stock price following the FDA approval of Foundayo, showing positive investor sentiment. |
| 2026-04-01 17:02:05 The competition between Eli Lilly's Foundayo and Novo Nordisk's oral Wegovy is a recurring theme, indicating a highly competitive landscape in the obesity treatment market. |
| 2026-04-01 17:02:05 Multiple articles discuss the FDA's approval of Eli Lilly's weight-loss pill, Foundayo, highlighting its significance in the obesity treatment market. |
| 2026-04-01 15:48:49 The approval of the weight-loss pill alleviates investor doubts and boosts confidence in Eli Lilly's future earnings potential. |
| 2026-04-01 15:48:49 The development and approval of the new oral obesity pill by Eli Lilly represent significant advancements in product offerings within the pharmaceutical industry. |
| 2026-04-01 15:48:49 Eli Lilly's stock saw a notable increase following the FDA approval of its weight-loss pill, indicating strong investor confidence. |
| 2026-04-01 15:48:49 The introduction of Eli Lilly's Foundayo intensifies competition in the obesity treatment market, particularly against established players like Novo Nordisk. |
| 2026-04-01 15:48:49 The approval of Eli Lilly's weight-loss pill by the FDA marks a significant regulatory milestone that positively impacts the company's stock performance and market position. |
| 2026-04-01 13:49:32 Eli Lilly's launch strategy includes making Foundayo available through an online pharmacy, enhancing accessibility for patients seeking weight loss solutions. |
| 2026-04-01 13:49:32 The expedited approval process for Foundayo highlights the efficacy of new FDA programs aimed at supporting innovative drug development. |
| 2026-04-01 13:49:32 Eli Lilly's stock experiences a significant increase following the approval of its weight-loss pill, indicating positive market reception and investor confidence. |
| 2026-04-01 13:49:32 The approval of Eli Lilly's obesity pill Foundayo intensifies competition in the weight-loss drug market, particularly against Novo Nordisk's earlier-launched obesity medication. |
| 2026-04-01 09:36:37 The acquisition marks a significant trend of pharmaceutical companies diversifying into new therapeutic areas, like sleep medicine. |
| 2026-04-01 09:36:37 Lilly is entering the wakefulness drug market with a promising new class of medications, indicating a strong focus on innovation. |
| 2026-04-01 09:36:37 Lilly's acquisition of Centessa demonstrates a strategic move to expand its portfolio beyond obesity into the sleep disorder market. |